GD
GMAB icon

Grandfield & Dodd’s Genmab GMAB Stock Holding History

Grandfield & Dodd’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03M Buy
37,633
+470
+1% +$12.5K 0.05% 111
2026
Q1 		$997K Sell
37,163
-935
-2% -$28K 0.06% 112
2025
Q4 		$1.17M Sell
38,098
-1,035
-3% -$32.3K 0.07% 108
2025
Q3 		$1.2M Buy
39,133
+630
+2% +$15.4K 0.07% 103
2025
Q2 		$795K Sell
38,503
-1,390
-3% -$28.5K 0.05% 116
2025
Q1 		$781K Buy
39,893
+6,160
+18% +$129K 0.05% 114
2024
Q4 		$704K Buy
33,733
+1,370
+4% +$30.1K 0.04% 123
2024
Q3 		$789K Buy
32,363
+6,610
+26% +$177K 0.05% 118
2024
Q2 		$647K Sell
25,753
-665
-3% -$18.9K 0.04% 127
2024
Q1 		$790K Buy
26,418
+860
+3% +$25.3K 0.05% 118
2023
Q4 		$814K Buy
25,558
+565
+2% +$17.7K 0.06% 112
2023
Q3 		$882K Buy
24,993
+3,285
+15% +$125K 0.06% 106
2023
Q2 		$825K Buy
21,708
+250
+1% +$9.97K 0.06% 112
2023
Q1 		$810K Buy
21,458
+1,340
+7% +$51.5K 0.06% 115
2022
Q4 		$853K Buy
20,118
+9,908
+97% +$408K 0.06% 111
2022
Q3 		$330K Buy
+10,210
New +$359K 0.03% 146

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Grandfield & Dodd's GMAB Position: Q2 2026 in Review

Grandfield & Dodd increased its Genmab (GMAB) stake by 1.3% in Q2 2026, buying an estimated $12.5K and bringing the position to 37,633 shares worth $1.03M. The position accounts for 0.05% of the portfolio, ranked #111.

Grandfield & Dodd first reported a position in GMAB in Q3 2022 and has held it in 16 quarters since. The position peaked at $1.2M in Q3 2025. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Grandfield & Dodd held 37,633 shares of Genmab worth $1.03M as of Q2 2026.
  • Grandfield & Dodd bought 470 Genmab shares in Q2 2026, an estimated $12.5K.
  • Genmab made up 0.05% of Grandfield & Dodd's portfolio in Q2 2026, its #111 holding.
  • Grandfield & Dodd first reported a position in Genmab in Q3 2022 and has held it in 16 quarters since.
  • Grandfield & Dodd's Genmab position peaked at $1.2M in Q3 2025.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Grandfield & Dodd's 13F filing for Q2 2026, filed 7 Aug 2026.